Please use this identifier to cite or link to this item:
https://www.arca.fiocruz.br/handle/icict/52905
Type
PreprintCopyright
Open access
Collections
- INI - Preprint [110]
Metadata
Show full item record1
CITATION
1
Total citation
1
Recent citation
0.53
Field Citation Ratio
0.19
Relative Citation Ratio
CLINICAL EFFECTS OF DURABILITY OF IMMUNOSUPPRESSION IN VIROLOGICALLY SUPPRESSED ART-INITIATING PERSONS WITH HIV IN LATIN AMERICA. A RETROSPECTIVE COHORT STUDY
HIV
Latin America
Sustained Virologic Response
Cumulative low CD4 counts
Author
Affilliation
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán (INCMNSZ). Mexico City, Mexico.
Vanderbilt University School of Medicine. Nashville, TN, USA.
Vanderbilt University School of Medicine. Nashville, TN, USA.
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán (INCMNSZ). Mexico City, Mexico.
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán (INCMNSZ). Mexico City, Mexico.
Fundación Huésped. Buenos Aires, Argentina.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Laboratório de Pesquisa Clínica em DST/AIDS. Rio de Janeiro, RJ, Brasil.
Fundación Arriarán y Universidad de Chile. Santiago, Chile.
Instituto Hondureño de Seguridad Social. Tegucigalpa, Honduras.
Universidad Peruana Cayetano Heredia. Lima, Perú.
Vanderbilt University School of Medicine. Nashville, TN, USA.
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán (INCMNSZ). Mexico City, Mexico.
Vanderbilt University School of Medicine. Nashville, TN, USA.
Vanderbilt University School of Medicine. Nashville, TN, USA.
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán (INCMNSZ). Mexico City, Mexico.
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán (INCMNSZ). Mexico City, Mexico.
Fundación Huésped. Buenos Aires, Argentina.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Laboratório de Pesquisa Clínica em DST/AIDS. Rio de Janeiro, RJ, Brasil.
Fundación Arriarán y Universidad de Chile. Santiago, Chile.
Instituto Hondureño de Seguridad Social. Tegucigalpa, Honduras.
Universidad Peruana Cayetano Heredia. Lima, Perú.
Vanderbilt University School of Medicine. Nashville, TN, USA.
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán (INCMNSZ). Mexico City, Mexico.
Abstract
Background: Clinical outcomes are rarely studied in virologically suppressed people living with HIV (PWH) and incomplete CD4 recovery. To explore whether time living with severe immunosuppression predict clinical outcomes better than baseline or time updated CD4, we estimated the association between cumulative percentage of time with CD4 <200 cells/μL during viral suppression (VS) (%tCD4<200), and mortality and comorbidities during 2000-2019. Methods: In a retrospective cohort analysis, we followed PWH initiating ART in Latin America from first VS (HIV-RNA<200 copies/μL) to death, virological failure or loss to follow-up. We fit Cox models to estimate risk of death and/or AIDS-defining and serious non-AIDS-defining events (ADE and SNADE -cancer, cardiovascular, liver, and renal diseases) by %tCD4<200 (continuous variable). We predicted survival probabilities for each event and calculated risks of hypothetical cases of different %tCD4<200. Findings: In 8,369 patients with 34·9 months of follow-up (median, IQR: 16·7, 69·1), 4,274 (51%) started ART with CD4<200 cells/μL. Median %tCD4<200 was 0% (IQR: 0, 15%). We identified 195 (2·3%) deaths and 584 (7·2%) patients with ADE/SNADE. For an increased %tCD4<200 of 15% (e.g., 15% vs. 0%), the adjusted relative hazard (aHR) of death was 1·27 (95% confidence interval [CI]: 1·19 - 1·35), of ADE/SNADE was 1·13 (95%CI: 1·09 - 1·17), of SNADE was 0·96 (95%CI: 0·89 - 1·02) and of death/ADE/SNADE was 1·11 (95%CI: 1·07 - 1·14). Estimates were similar after adjusting for time updated CD4 count. Interpretation: In virologically suppressed PWH, increased time living with severe immunosuppression had an increased risk of death and ADE/SNADE in this Latin American cohort, independently of time updated CD4 count.
Keywords
AIDS defining and non-AIDS defining eventsHIV
Latin America
Sustained Virologic Response
Cumulative low CD4 counts
Share